In summary, this study will provide the latest evidence to support the susceptibility of SAMM50 gene polymorphisms and NAFLD, and provide strategies for the prevention and treatment of NAFLD. The gene discussed is SAMM50; the disease is metabolic dysfunction-associated steatotic liver disease.